Patents by Inventor Raju Kucherlapati
Raju Kucherlapati has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20040010810Abstract: The subject invention provides non-human mammalian hosts characterized by inactivated endogenous Ig loci and functional human Ig loci for response to an immunogen to produce human antibodies or analogs thereof. The hosts are produced by multiple genetic modifications of embryonic cells in conjunction with breeding. Different strategies are employed for recombination of the human loci randomly or at analogous host loci. Chimeric and transgenic mammals, particularly mice, are provided, having stably integrated large, xenogeneic DNA segments. The segments are introduced by fusion with yeast spheroplasts comprising yeast artificial chromosomes (YACs) which include the xenogeneic DNA segments and a selective marker such as HPRT, and embryonic stem cells.Type: ApplicationFiled: June 4, 2003Publication date: January 15, 2004Applicant: ABGENIX, INC.Inventors: Raju Kucherlapati, Aya Jakobovits, Sue Klapholz, Daniel G. Brenner, Daniel J. Capon
-
Patent number: 6673986Abstract: The subject invention provides non-human mammalian hosts characterized by inactivated endogenous Ig loci and functional human Ig loci for response to an immunogen to produce human antibodies or analogs thereof. The hosts are produced by multiple genetic modifications of embryonic cells in conjunction with breeding. Different strategies are employed for recombination of the human loci randomly or at analogous host loci. Chimeric and transgenic mammals, particularly mice, are provided, having stably integrated large, xenogeneic DNA segments. The segments are introduced by fusion with yeast spheroplasts comprising yeast artificial chromosomes (YACs) which include the xenogeneic DNA segments and a selective marker such as HPRT, and embryonic stem cells.Type: GrantFiled: March 15, 1993Date of Patent: January 6, 2004Assignee: Abgenix, Inc.Inventors: Raju Kucherlapati, Aya Jakobovits, Sue Klapholz, Daniel G. Brenner, Daniel J. Capon
-
Publication number: 20030229905Abstract: The subject invention provides non-human mammalian hosts characterized by inactivated endogenous Ig loci and functional human Ig loci for response to an immunogen to produce human antibodies or analogs thereof. The hosts are produced by multiple genetic modifications of embryonic cells in conjunction with breeding. Different strategies are employed for recombination of the human loci randomly or at analogous host loci. Chimeric and transgenic mammals, particularly mice, are provided, having stably integrated large, xenogeneic DNA segments. The segments are introduced by fusion with yeast spheroplasts comprising yeast artificial chromosomes (YACs) which include the xenogeneic DNA segments and a selective marker such as HPRT, and embryonic stem cells.Type: ApplicationFiled: April 21, 2003Publication date: December 11, 2003Applicant: Abqenix, Inc.Inventors: Raju Kucherlapati, Aya Jakobovits, Sue Klapholz, Daniel G. Brenner, Daniel J. Capon
-
Patent number: 6657103Abstract: Antibodies with fully human variable regions against a specific antigen can be prepared by administering the antigen to a transgenic animal which has been modified to produce such antibodies in response to antigenic challenge, but whose endogenous loci have been disabled. Various subsequent manipulations can be performed to obtain either antibodies per se or analogs thereof.Type: GrantFiled: September 4, 1997Date of Patent: December 2, 2003Assignee: Abgenix, Inc.Inventors: Raju Kucherlapati, Aya Jakobovits, Sue Klapholz, Daniel G. Brenner, Daniel J. Capon
-
Publication number: 20030070185Abstract: The present invention relates to transgenic non-human animals that are engineered to contain human immunoglobulin gene loci. In particular, animals in accordance with the invention possess human Ig loci that include plural variable (VH and V&kgr;) gene regions. Advantageously, the inclusion of plural variable region genes enhances the specificity and diversity of human antibodies produced by the animal. Further, the inclusion of such regions enhances and reconstitutes B-cell development to the animals, such that the animals possess abundant mature B-cells secreting extremely high affinity antibodies.Type: ApplicationFiled: February 19, 2002Publication date: April 10, 2003Inventors: Aya Jakobovits, Raju Kucherlapati, Susan Klapholz, Michael J. Mendez, Larry Green
-
Patent number: 6514752Abstract: Homologous recombination is employed to inactivate genes, particularly genes associated with MHC antigens. Particularly, the &bgr;2-microglobulin gene is inactivated for reducing or eliminating the expression of functional Class I MHC antigens. The resulting cells may be used as universal donor cells. In addition, embryonic stem cells may be modified by homologous recombination for use in producing chimeric or transgenic mammalian hosts, which may be used as source of universal donor organs, or as models for drug and transplantation therapies. Methods for homologous recombination in non-transformed mammalian somatic cells are also described.Type: GrantFiled: May 18, 1995Date of Patent: February 4, 2003Assignee: Cell Genesys, Inc.Inventors: Raju Kucherlapati, Beverly H. Koller, Oliver Smithies, Robert B. Dubridge, Gary Greenburg, Daniel J. Capon, Steven R. Williams, Mariona Lourdes Arbones De Rafael
-
Patent number: 6162963Abstract: The subject invention provides non-human mammalian hosts characterized by inactivated endogenous Ig loci and functional human Ig loci for response to an immunogen to produce human antibodies or analogs thereof. The hosts are produced by multiple genetic modifications of embryonic cells in conjunction with breeding. Different strategies are employed for recombination of the human loci randomly or at analogous host loci. Chimeric and transgenic mammals, particularly mice, are provided, having stably integrated large, xenogeneic DNA segments. The segments are introduced by fusion with yeast spheroplasts comprising yeast artificial chromosomes (YACs) which include the xenogeneic DNA segments and a selective marker such as HPRT, and embryonic stem cells.Type: GrantFiled: June 5, 1995Date of Patent: December 19, 2000Assignee: Abgenix, Inc.Inventors: Raju Kucherlapati, Aya Jakobovits, Sue Klapholz, Daniel G. Brenner, Daniel J. Capon
-
Patent number: 6150584Abstract: Fully human antibodies against a specific antigen can be prepared by administering the antigen to a transgenic animal which has been modified to produce such antibodies in response to antigenic challenge, but whose endogenous loci have been disabled. Various subsequent manipulations can be performed to obtain either antibodies per se or analogs thereof.Type: GrantFiled: October 2, 1996Date of Patent: November 21, 2000Assignee: Abgenix, Inc.Inventors: Raju Kucherlapati, Aya Jakobovits, Daniel G. Brenner, Daniel J. Capon, Sue Klapholz
-
Patent number: 6139835Abstract: Homologous recombination is employed to inactivate genes, particularly genes associated with MHC antigens. Particularly, the .beta..sub.2- microglobulin gene is inactivated for reducing or eliminating the expression of functional Class I MHC antigens. The resulting cells may be used as allogeneic donor cells. Methods for homologous recombination in non-transformed mammalian somatic cells are also described.Type: GrantFiled: May 18, 1995Date of Patent: October 31, 2000Assignee: Cell Genesys, Inc.Inventors: Raju Kucherlapati, Beverly H. Koller, Oliver Smithies, Robert B. Dubridge, Gary Greenburg, Daniel J. Capon, Steven R. Williams, Mariona Lourdes Arbones De Rafael
-
Patent number: 6114598Abstract: The subject invention provides non-human mammalian hosts characterized by inactivated endogenous Ig loci and functional human Ig loci for response to an immunogen to produce human antibodies or analogs thereof. The hosts are produced by multiple genetic modifications of embryonic cells in conjunction with breeding. Different strategies are employed for recombination of the human loci randomly or at analogous host loci. Chimeric and transgenic mammals, particularly mice, are provided, having stably integrated large, xenogeneic DNA segments. The segments are introduced by fusion with yeast spheroplasts comprising yeast artificial chromosomes (YACs) which include the xenogeneic DNA segments and a selective marker such as HPRT, and embryonic stem cells.Type: GrantFiled: June 5, 1995Date of Patent: September 5, 2000Assignee: Abgenix, Inc.Inventors: Raju Kucherlapati, Aya Jakobovits, Sue Kalpholz, Daniel G. Brenner, Daniel J. Capon
-
Patent number: 6075181Abstract: Antibodies with fully human variable regions against a specific antigen can be prepared by administering the antigen to a transgenic animal which has been modified to produce such antibodies in response to antigenic challenge, but whose endogenous loci have been disabled. Various subsequent manipulations can be performed to obtain either antibodies per se or analogs thereof.Type: GrantFiled: June 7, 1995Date of Patent: June 13, 2000Assignee: Abgenix, Inc.Inventors: Raju Kucherlapati, Aya Jakobovits, Sue Klapholz, Daniel G. Brenner, Daniel J. Capon
-
Patent number: 5939598Abstract: The subject invention provides non-human mammalian hosts characterized by inactivated endogenous Ig loci. The hosts are produced by repetitive transformations of embryonic stem cells by homologous recombination, preferably in conjunction with breeding. Different strategies are employed for recombination of the human loci randomly or at analogous host loci.Type: GrantFiled: July 30, 1992Date of Patent: August 17, 1999Assignee: Abgenix, Inc.Inventors: Raju Kucherlapati, Aya Jakobovits
-
Patent number: 5574205Abstract: Homologous recombination is employed to inactivate genes, particularly genes associated with MHC antigens. Particularly, each of the .beta..sub.2- microglobulin gene and the IFN-.gamma.R gene is inactivated for reducing or eliminating the expression of functional MHC antigens. The resulting cells may be used as universal donor cells. In addition, embryonic stem cells may be modified by homologous recombination for use in producing chimeric or transgenic mammalian hosts, which may be used as source of universal donor organs, or as models for drug and transplantation therapies. Methods for homologous recombination in non-transformed mammalian somatic cells are also described.Type: GrantFiled: December 30, 1993Date of Patent: November 12, 1996Assignee: Cell GenesysInventors: Raju Kucherlapati, Beverly H. Koller, Oliver Smithies, Robert B. Dubridge, Gary Greenburg, Daniel J. Capon, Steven R. Williams, Mariona L. A. De Rafael
-
Patent number: 5413923Abstract: Homologous recombination is employed to inactivate genes, particularly genes associated with MHC antigens. Particularly, the .beta..sub.2 -microglobulin gene is inactivated for reducing or eliminating Class I MHC antigens. The resulting cells may be used as universal donors. In addition, embryonic stem cells may be modified by homologous recombination for use in producing chimeric or transgenic mammalian hosts, which may be used as source of universal donor organs, or as models for drug and transplantation therapies.Type: GrantFiled: December 11, 1992Date of Patent: May 9, 1995Assignees: Cell Genesys, Inc., Univ. of North Carolina at Chapel HillInventors: Raju Kucherlapati, Beverly H. Koller, Oliver Smithies